Injectable Mesenchymal Stem Cell Therapy for Large Cartilage Defects—A Porcine Model
Article first published online: 26 JUL 2007
Copyright © 2007 AlphaMed Press
Volume 25, Issue 11, pages 2964–2971, November 2007
How to Cite
Lee, K. B.L., Hui, J. H.P., Song, I. C., Ardany, L. and Lee, E. H. (2007), Injectable Mesenchymal Stem Cell Therapy for Large Cartilage Defects—A Porcine Model. STEM CELLS, 25: 2964–2971. doi: 10.1634/stemcells.2006-0311
- Issue published online: 2 JAN 2009
- Article first published online: 26 JUL 2007
- Manuscript Accepted: 18 JUN 2007
- Manuscript Received: 24 MAY 2006
- Cartilage defects;
- Minimally invasive;
- Mesenchymal stem cells;
- Hyaluronic acid;
Current techniques in biological resurfacing of cartilage defects require an open arthrotomy or arthroscopy and involve the direct transplantation of isolated cells and/or scaffolds or whole tissue grafts with chondrogenic potential onto the cartilage defect. Our study investigates the possibility of direct intra-articular injection of mesenchymal stem cells suspended in hyaluronic acid (HA) as an alternative to the much more invasive methods currently available. A partial-thickness (without penetration of the subchondral bone) cartilage defect was created in the medial femoral condyle of an adult minipig. Mesenchymal stem cells from the iliac crest marrow of the same pig harvested in a separate procedure and suspended in 2 milliliters of hylan G-F 20 (Synvisc) were injected intra-articularly after the creation of the defect. This was followed by two more injections of hylan G-F 20 (HA) at weekly intervals. Either saline or HA was injected into the knees of the controls. The pigs were sacrificed at 6 and 12 weeks for morphological and histological analysis. The cell-treated groups showed improved cartilage healing both histologically and morphologically at 6 and 12 weeks compared with both controls. The use of intra-articular injections of mesenchymal stem cells suspended in HA is a viable option for treating large cartilage defects. This would be further explored in clinical trials.
Disclosure of potential conflicts of interest is found at the end of this article.